Navigating the evolving diagnostic and therapeutic landscape of low-and intermediate-risk prostate cancer  

作　　者：Fabio Zattoni Fabio Matrone Roberto Bortolus GianlucaGiannarini 

机构地区：[1]Urologic Unit,Department of Surgery,Oncology and Gastroenterology,University of Padova,Padua,Italy [2]Department of Radiotherapy,National Cancer Institute(CRO),Aviano 33081,Italy [3]Urology Unit,Santa Maria Della Misericordia University Hospital,Udine 33100,Italy

出　　处：《Asian Journal of Andrology》2024年第6期549-556,共8页亚洲男性学杂志（英文版）

摘　　要：In this nonsystematic review of the literature,we explored the changing landscape of detection and treatment of low-and intermediate-risk prostate cancer(PCa).Through emphasizing improved cancer assessment with histology classification and genomics,we investigated key developments in PCa detection and risk stratification.The pivotal role of prostate magnetic resonance imaging(MRI)in the novel diagnostic pathway is examined,alongside the benefits and drawbacks of MRI-targeted biopsies for detection and tumor characterization.We also delved into treatment options,particularly active surveillance for intermediate-risk PCa.Outcomes are compared between intermediate-and low-risk patients,offering insights into tailored management.Surgical techniques,including Retzius-sparing surgery,precision prostatectomy,and partial prostatectomy for anterior cancer,are appraised.Each technique has the potential to enhance outcomes and minimize complications.Advancements in technology and radiobiology,including computed tomography(CT)/MRI imaging and positron emission tomography(PET)fusion,allow for precise dose adjustment and daily target monitoring with imaging-guided radiotherapy,opening new ways of tailoring patients’treatments.Finally,experimental therapeutic approaches such as focal therapy open new treatment frontiers,although they create new needs in tumor identification and tracking during and after the procedure.

关 键 词：intermediate-risk prostate cancer MRI PET prostate cancer radical prostatectomy 

分 类 号：R737.25[医药卫生—肿瘤]